PUBLISHED ASSESSMENT

Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Commercially-insured individuals aged 6 months through 64 years: Self-controlled case series analyses - PubMed

This compact public record contains an assessment and source links. It does not contain article text, reader identity, browsing history, or private notes.

Historical provenance limit: this assessment has a recorded retrieval URL from before Beaconwright’s current publisher-verification boundary. It has not been reverified under the current boundary.

Open original article

The study presents substantial evidence from a large, multi-database self-controlled analysis and transparently reports two safety signals alongside seven null findings. Its interpretation is constrained by unavailable supplementary analyses, proprietary data, limited absolute-risk information, and sparse discussion in the abstract of multiplicity, outcome misclassification, and generalizability.

Evidence support

Substantial (74/100)

A prespecified self-controlled case-series design covered nearly 10 million vaccinees across three databases.
Exact incidence-rate ratios and confidence intervals are reported for the principal findings.
Subsequent FDA action supports the febrile-seizure signal, while a separate Medicare analysis provides limited context for the TIA finding.
Absolute event counts, coding validity, sensitivity results, and complete database-specific estimates were not available for review.

Balance & context

Substantial (66/100)

The article reports both null results and statistically significant signals rather than presenting uniformly reassuring findings.
It calls for continued surveillance and weighs possible risks against vaccination benefits.
The abstract provides little discussion of claims misclassification, multiple testing, alternative explanations, or commercial-insurance generalizability.
Calling overall risk “minimal” is difficult to evaluate without absolute-risk estimates.

Transparency

Substantial (74/100)

Authors, affiliations, publication dates, DOI, outcomes, design, statistical model, estimates, funding, and competing interests are disclosed.
Risk intervals and adjustment for seasonality are identified.
Underlying records, analytic code, detailed outcome definitions, and supplementary analyses were not directly inspectable.

Confidence and coverage

Confidence in this analysis: Moderate confidence

Evidence coverage: Partial coverage

Assessment relied mainly on the abstract and indexed full-text excerpts; complete tables and supplementary methods were inaccessible.
Proprietary claims data prevented independent replication or patient-level verification.

Core methods and results were clearly reported and partly corroborated by FDA materials.
Lack of access to complete tables, supplements, and proprietary data limits methodological verification.

Sources considered

FDA Safety Labeling Change Notification for Fluzone — FDA cited the study and an additional season of surveillance when requiring labeling about increased first-day febrile-seizure risk in young children.
Safety monitoring of 2023–2024 influenza vaccination among U.S. Medicare beneficiaries aged 65 years and older — A separate SCCS analysis found small TIA/stroke signals in an older population, though with different intervals and incomplete consistency across sensitivity analyses.
A Structured Review of Electronic Coding Algorithms for Febrile Seizure — Describes the strengths and limitations of identifying febrile seizures through administrative coding.

This assesses evidence and presentation; it is not an overall truth verdict.

Reassess

⚠ Paid reassessment incurs a charge. Opening this page does not start a run or incur a charge.

To request a new assessment, sign in to My library, watch this record, and select Request new assessment. Requests await separate approval and do not themselves start a paid run.

A new assessment may differ. Earlier published results remain in history.

Open My library

Assessment history

Published assessment trend

Available public snapshots only; this is not a count of all executions. Corrections may include earlier scores. Gaps mean not scored or not recorded. Different scores do not establish changed source evidence.

Evidence support — solid blueBalance & context — dashed purpleTransparency — dotted green

Reassess ⚠

Recorded public scores (0–100)
Date	Evidence support	Balance & context	Transparency
2026-09-12 (current)	74	66	74